{"id":"atenolol-pill","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Fatigue"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Bradycardia"},{"rate":"5-10","effect":"Hypotension"},{"rate":"5","effect":"Cold extremities"},{"rate":"1-5","effect":"Bronchospasm (in susceptible patients)"},{"rate":"2-5","effect":"Sexual dysfunction"}]},"_chembl":{"chemblId":"CHEMBL24","moleculeType":"Small molecule","molecularWeight":"266.34"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atenolol selectively blocks beta-1 adrenergic receptors on cardiac tissue, decreasing heart contractility and heart rate. This reduces cardiac oxygen demand and lowers blood pressure. The drug is cardioselective at therapeutic doses, meaning it preferentially targets cardiac beta-1 receptors over beta-2 receptors in the lungs and vasculature.","oneSentence":"Atenolol is a beta-1 selective adrenergic receptor antagonist that reduces heart rate and blood pressure by blocking the effects of norepinephrine and epinephrine on the heart.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:19:19.018Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Angina pectoris"},{"name":"Acute myocardial infarction"},{"name":"Atrial fibrillation for rate control"}]},"trialDetails":[{"nctId":"NCT07298993","phase":"PHASE4","title":"Deprescribing Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF)","status":"ENROLLING_BY_INVITATION","sponsor":"Weill Medical College of Cornell University","startDate":"2026-02-02","conditions":"Heart Failure, HFpEF, HFpEF - Heart Failure With Preserved Ejection Fraction","enrollment":240},{"nctId":"NCT06670690","phase":"NA","title":"Comparison Between Atenolol,Propnalol and Ivabradine","status":"COMPLETED","sponsor":"Menoufia University","startDate":"2023-09-01","conditions":"Intraoperative Bleeding","enrollment":120},{"nctId":"NCT01326676","phase":"PHASE3","title":"Polypill Effects on Sub Clinical Atherosclerosis (PESCA) Trial","status":"WITHDRAWN","sponsor":"Imperial College London","startDate":"2011-02","conditions":"Cardiovascular Disease","enrollment":""},{"nctId":"NCT04931108","phase":"PHASE4","title":"The Effect of Nitrendipine/Atenolol Combination on Blood Pressure Variability.","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2021-09-27","conditions":"Hypertension","enrollment":32},{"nctId":"NCT01313702","phase":"PHASE3","title":"Single Pill to Avert Cardiovascular Events","status":"WITHDRAWN","sponsor":"Hospital do Coracao","startDate":"2012-10","conditions":"Cardiovascular Disease","enrollment":""},{"nctId":"NCT05106179","phase":"PHASE4","title":"The Efficacy and Safety of Beta-blockers Drugs in Adults With Spinal Hemangioma","status":"UNKNOWN","sponsor":"Center for Vascular Pathology, Moscow","startDate":"2021-12","conditions":"Spinal Tumor, Spinal Hemangioma, Beta Blocker Toxicity","enrollment":1000},{"nctId":"NCT02467400","phase":"EARLY_PHASE1","title":"Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2015-07-01","conditions":"Osteoporosis, Age-Related","enrollment":165},{"nctId":"NCT03245996","phase":"PHASE4","title":"The Impact of Heart Rate on Central Blood Pressure in Sick Sinus Syndrome Patients With a Permanent Cardiac Pacemaker","status":"COMPLETED","sponsor":"Tartu University Hospital","startDate":"2015-06","conditions":"Aortic Blood Pressure","enrollment":27},{"nctId":"NCT01795235","phase":"NA","title":"Study of Glucagon, Ghrelin and Growth Hormone as Counterregulatory Hormones","status":"UNKNOWN","sponsor":"University of Virginia","startDate":"2012-12","conditions":"Healthy","enrollment":6},{"nctId":"NCT01057537","phase":"PHASE3","title":"UMPIRE - Use of a Multidrug Pill In Reducing Cardiovascular Events","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2010-06","conditions":"Cardiovascular Diseases","enrollment":2004}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"LOSS OF CONSCIOUSNESS"},{"count":1,"reaction":"MIGRAINE"},{"count":1,"reaction":"TRANSIENT ISCHAEMIC ATTACK"},{"count":1,"reaction":"TRICUSPID VALVE INCOMPETENCE"}],"_approvalHistory":[],"publicationCount":26,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Atenolol Pill","genericName":"Atenolol Pill","companyName":"Tartu University Hospital","companyId":"tartu-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atenolol is a beta-1 selective adrenergic receptor antagonist that reduces heart rate and blood pressure by blocking the effects of norepinephrine and epinephrine on the heart. Used for Hypertension, Angina pectoris, Acute myocardial infarction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}